Account wins from the 05/23/06 News Brief

Share this article:
Merck selected Interlink Healthcare Communications as pre-launch medical education agency of record for two experimental atherosclerosis compounds. The compounds, in Phase III clinical trials, are known as MK-524A and MK-524B. Merck hopes to file new drug applications in 2007. A novel approach to treating HDL-C, or “good cholesterol,” MK-0524A combines Merck’s extended-release niacin with an ingredient to inhibit flushing, for use alone or with a statin. MK-0524B combines MK-0524A with Merck’s Zocor (simvastatin), which is approved for lowering LDL cholesterol, or "bad cholesterol." Interlink will develop scientific and strategic foundations for both drugs. Duramed Pharmaceuticals has retained Pace, part of Lowe Healthcare Worldwide, as consumer and professional agency for the relaunch of ParaGard (intrauterine copper contraceptive). Duramed acquired ParaGard when it bought FEI Women's Health last year for $281.5 million. MBL Communications has appointed independent media representative company Sherburne Medical Media to represent various accounts for the publications CNS Spectrums and Primary Psychiatry and for Psychiatry Weekly.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.